Inventiva's Lanifibranor Significantly Reduces NAFLD and Improves Type 2 Diabetes Control, Phase 2 Study Shows
Portfolio Pulse from Vandana Singh
Inventiva SA (NASDAQ:IVA) announced positive topline results of a Phase 2 clinical study evaluating lanifibranor in patients with NAFLD and type 2 diabetes mellitus. The study achieved the primary efficacy endpoint with a 44% reduction of Intra Hepatic Triglycerides and met multiple secondary metabolic endpoints. IVA shares are up 26.40% at $4.64 during the premarket session.
June 14, 2023 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva's lanifibranor demonstrated positive results in a Phase 2 study for NAFLD and type 2 diabetes, leading to a 26.40% increase in IVA shares during the premarket session.
The positive results from the Phase 2 clinical study of lanifibranor in patients with NAFLD and type 2 diabetes mellitus indicate a potential successful treatment option. This achievement of the primary efficacy endpoint and multiple secondary metabolic endpoints confirms the cardiometabolic benefit of lanifibranor, which is likely to boost investor confidence in Inventiva and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100